Precision BioSciences Unveils Promising ELIMINATE-B Trial Results

Precision BioSciences ( (DTIL) ) has provided an update.

On November 10, 2025, Precision BioSciences announced significant findings from its ELIMINATE-B clinical trial, which evaluates the PBGENE-HBV therapy for hepatitis B. The trial demonstrated consistent antiviral activity and durable reductions in hepatitis B surface antigen across various dose levels, with no dose-limiting toxicities observed. The promising results, including direct evidence of HBV DNA editing, suggest a potential path to a cure, positioning the company favorably in the gene editing landscape and offering hope for stakeholders seeking effective hepatitis B treatments.

The most recent analyst rating on (DTIL) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Spark’s Take on DTIL Stock

According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.

The overall stock score is primarily impacted by the company’s poor financial performance, characterized by declining revenues and significant losses. Technical analysis provides a slightly more positive outlook with some bullish momentum, but valuation remains a concern due to the negative P/E ratio. The absence of earnings call data and corporate events means these factors do not influence the score.

To see Spark’s full report on DTIL stock, click here.

More about Precision BioSciences

Precision BioSciences operates in the biotechnology industry, focusing on gene editing technologies. The company develops in vivo gene editing therapies, with a particular emphasis on addressing chronic diseases such as hepatitis B through innovative treatments like PBGENE-HBV.

Average Trading Volume: 116,924

Technical Sentiment Signal: Hold

Current Market Cap: $81.4M

See more data about DTIL stock on TipRanks’ Stock Analysis page.